Yale SPORE in Lung Cancer News
A new study from Yale Cancer Center characterizes the functional link between drug resistance and central nervous system (CNS) relapse. The findings from a study led by Don Nguyen, PhD, BS, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Yale Cancer Center Director for Research Development, were recently published in the journal Nature Communications.
- December 13, 2022
The Yale School of Public Health’s Department of Biostatistics is experiencing the end of an era. Four senior faculty representing more than 120 years of teaching and research experience have either recently retired or soon will retire. The work of these distinguished leaders in biostatistics at Yale – Robert Makuch, Theodore Holford, Peter Peduzzi, and Daniel Zelterman - helped define the department as it exists today.
- December 05, 2022
In a new study, Yale Cancer Center researchers found molecular explanations for why some lung tumors respond better to certain drugs than others. The research should help improve drug selection for lung cancer patients with different mutations in the EGF receptor, using a precision medicine approach to treatment.
- November 15, 2022
Q&A with Roy Herbst, MD, PhD, medical oncologist, in recognition of Lung Cancer Awareness Month.
- September 20, 2022Source: MED Page Today
An updated analysis of the phase III ADAURA trial revealed a median disease-free survival (DFS) of 5.5 years for early-stage, EGFR-positive non-small cell lung cancer (NSCLC) patients who received osimertinib (Tagrisso) in the postoperative setting, with nearly three in four patients treated with the adjuvant therapy free of disease at 4 years.
- September 14, 2022Source: Cancer Network
It has been 20 years since the discovery of EGFR mutations and almost 25 years since we first used EGFR inhibitors in the clinic. This resulted in a paradigm shift regarding the way we think about lung cancer. Now that we have drugs which target growth factor receptors, and we use them to slow the growth of tumors, giving rise to dramatic responses.
- September 11, 2022
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years. The new results also indicated that the use of osimertinib reduced the risk of disease recurrence in the brain and spinal cord. The results from the study were presented today at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
- June 03, 2022
A combination of the drugs ramucirumab and pembrolizumab reduced risk of death by 31% compared with the standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.
- May 17, 2022Source: Journal for ImmunoTherapy of Cancer
This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma.
- May 09, 2022
New research from Yale Cancer Center provides a new understanding of patients’ views of artificial intelligence (AI) in healthcare. While comfort level varied by clinical application, most respondents had positive views about AI’s ability to improve care. Concerns surfaced when potential for misdiagnosis, privacy breaches, reduced time with clinicians, and increased costs were discussed.